Show simple item record

A Robust Phenotypic High-Throughput Antiviral Assay for the Discovery of Rabies Virus Inhibitors

dc.contributor.authorXinyu Wang
dc.contributor.authorWinston Chiu
dc.contributor.authorHugo Klaassen
dc.contributor.authorArnaud Marchand
dc.contributor.authorPatrick Chaltin
dc.contributor.authorJohan Neyts
dc.contributor.authorDirk Jochmans
dc.contributor.otherRega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Herestraat 49 Box 1043, 3000 Leuven, Belgium
dc.contributor.otherRega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Herestraat 49 Box 1043, 3000 Leuven, Belgium
dc.contributor.otherCistim Leuven vzw, Bioincubator 2, Gaston Geenslaan 2, 3001 Leuven, Belgium
dc.contributor.otherCistim Leuven vzw, Bioincubator 2, Gaston Geenslaan 2, 3001 Leuven, Belgium
dc.contributor.otherCistim Leuven vzw, Bioincubator 2, Gaston Geenslaan 2, 3001 Leuven, Belgium
dc.contributor.otherRega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Herestraat 49 Box 1043, 3000 Leuven, Belgium
dc.contributor.otherRega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Herestraat 49 Box 1043, 3000 Leuven, Belgium
dc.date.accessioned2023-12-22T14:48:58Z
dc.date.accessioned2025-10-08T09:03:34Z
dc.date.available2025-10-08T09:03:34Z
dc.date.issued01-11-2023
dc.identifier.urihttp://digilib.fisipol.ugm.ac.id/repo/handle/15717717/38729
dc.description.abstractRabies virus (RABV) causes severe neurological symptoms in mammals. The disease is almost inevitably lethal as soon as clinical symptoms appear. The use of rabies immunoglobulins (RIG) and vaccination in post-exposure prophylaxis (PEP) can provide efficient protection, but many people do not receive this treatment due to its high cost and/or limited availability. Highly potent small molecule antivirals are urgently needed to treat patients once symptoms develop. In this paper, we report on the development of a high-throughput phenotypic antiviral screening assay based on the infection of BHK-21 cells with a fluorescent reporter virus and high content imaging readout. The assay was used to screen a repurposing library of 3681 drugs (all had been studied in phase 1 clinical trials). From this series, salinomycin was found to selectively inhibit viral replication by blocking infection at the entry stage. This shows that a high-throughput assay enables the screening of large compound libraries for the purposes of identifying inhibitors of RABV replication. These can then be optimized through medicinal chemistry efforts and further developed into urgently needed drugs for the treatment of symptomatic rabies.
dc.language.isoEN
dc.publisherMDPI AG
dc.subject.lccMicrobiology
dc.titleA Robust Phenotypic High-Throughput Antiviral Assay for the Discovery of Rabies Virus Inhibitors
dc.typeArticle
dc.description.keywordsrabies virus
dc.description.keywordshigh-throughput screening
dc.description.keywordsdrug repurposing
dc.description.keywordsantiviral therapy
dc.description.doi10.3390/v15122292
dc.title.journalViruses
dc.identifier.e-issn1999-4915
dc.identifier.oaioai:doaj.org/journal:f4ea8d2c9bd5477dac2b99e90efdfdf9
dc.journal.infoVolume 15, Issue 12


This item appears in the following Collection(s)

Show simple item record